TLR9 engagement on CD4 T lymphocytes represses (gamma)-radiation-induced apoptosis through activation of checkpoint kinase response elements

Blood

Volumn 111, Issue 5, 2008, Pages 2704-2713

  Zheng, Liqin ^a   Asprodites, Nicole ^a   Keene, Angela H ^a   Rodriguez, Paulo ^a   Brown, Kevin D ^b   Davila, Eduardo ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; TOLL LIKE RECEPTOR 9; ANTIGEN; LIGAND; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; TLR9 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL PROTECTION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GAMMA IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; ANIMAL; CELL CYCLE; CELL SURVIVAL; CYTOLOGY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYMOLOGY; GAMMA RADIATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RADIATION DOSE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; GAMMA RAYS; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; WHOLE-BODY IRRADIATION;

EID: 41949127055     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-104141     Document Type: Article

References (75)

1. Leen AM. Rooney CM. Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-265.
2. Blattman JN. Greenberg PD. Cancer immunotherapy: a treatment tor the masses. Science. 2004;305:200-205.
3. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide / protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol. 2000;165:539-547.
4. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63:3281-3288.
5. Rosenberg SA, Yang JC, Restifo NP Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Owen JB, Coia LR. Hanks GE. Recent patterns o1 growth in radiation therapy facilities in the United States: a patterns of care study report. Int J Ra-diat Oncol Biol Phys. 1992;24:983-986.
7. Blackett NM, Marsh JC, Gordon MY, Okell SF, Aguado M. Simultaneous assay by six methods of the effect on haemopoietic precursor cells of adriamycin, methyl CCNU, 6OC0 gamma-rays, vinblastine, and cytosine arabinoside. Exp Hematol. 1978;6:2-8.
8. Lohrmann HP, Schreml W. Cytotoxic drugs and the granulopoietic system. Recent Results Cancer Res. 1982;81:1-222.
9. Mason KA, Ariga H, Neal R et al. Targeting tolllike receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005;11:361-369.
10. Mason KA, Neal R, Hunter N et al. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Ra-diother Oncol. 2006;80:192-198.
11. Meng Y. Carpentier AF. Chen L et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer. 2005;116:992-997.
12. Milas L, Mason KA, Ariga H et al. CpG oligode-oxynucleotide enhances tumor response to radiation. Cancer Res. 2004;64:5074-5077.
13. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003;9:3105-3114.
14. Nair CK, Parida DK, Nomura T. Radioprotectors in radiotherapy. J Radiat Res (Tokyo). 2001;42: 21-37.
15. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85-95.
16. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-995.
17. Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood. 2002;100:2537-2545.
18. Jozsef L, Khreiss T, Filep JG. CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J. 2004;18:1776-1778.
19. Kuo CC, Liang SM, Liang CM. CpG-B oligode-oxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation. J Biol Chem. 2006;281:38200-38207.
20. Sester DP, Brion K, Trieu Aet al. CpG DNA activates survival in murine macrophages through TLR9 and the phosphatidylinositol 3-kinase-Akt pathway. J Immunol. 2006;177:4473-4480.
21. Bohnhorst J, Rasmussen T. Moen SH et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20:1138-1144.
22. Sohn WJ, Lee KW, Choi SY et al. CpG-oligode-oxynucleotide protects immune cells from gamma-irradiation-induced cell death. Mol Immunol. 2006;43:1163-1171.
23. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998:160:5898-5906.
24. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol. 1999;11:2015-2024.
25. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpG- oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol. 1999;29:1209-1218.
26. Caron G, Duluc D, Fremaux I et al. Direct stimulation of human T cells via TLRS and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005;175:1551-1557.
27. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA. 2004;101:3029-3034.
28. Matsuguchi T, Takagi K, Musikacharoen T, Yoshi-kai Y. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood. 2000;95:1378-1385.
29. Caramalho I, Lopes-Garvalho T, Ostler D et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003;197:403-411.
30. Peng G, Guo Z, Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005;309:1380-1384.
31. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA. 2004;101:3029-3034.
32. Matsuguchi T, Takagi K, Musikacharoen T, Yoshi-kai Y. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood. 2000:95:1378-1385.
33. Cottalorda A, Verschelde C, Marcais A et al. TLR2 engagement on CD8 T cells lowers the threshold-for optimal antigen-induced T cell activation. Eur J Immunol. 2006;36:1684-1693.
34. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065-6073.
35. Chiffoleau E, Heslan JM, Heslan M et al. TLR9 ligand enhances proliferation of rat CD4+ Tcell and modulates suppressive activity mediated by CD4+ CD25+Tcell. Int Immunol. 2007;19:193-201.
36. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007;14:32-43.
37. Hong SJ, Dawson TM. Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci. 2004;25:259-264.
38. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 2001;21:4129-4139.
39. Lee CH, Chung JH. The hCdsl (Chk2)-FHAdo-main is essential for a chain of phosphorylation events on hCdsl that is induced by ionizing radiation. J Biol Chem. 2001;276:30537-30541.
40. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1: 179-186.
41. Zhou BB. Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433-439.
42. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499-506.
43. Barrios Sosa AC, Yakushijin K, Home DA. A practical synthesis of (Z)-debromohymenialdisine. J Org Chem. 2000;65:610-611.
44. Curman D, Cinel B, Williams DE et al. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem. 2001;276:17914-17919.
45. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Gom-mun. 1996;219:778-783.
46. Wang Q, Fan S, Eastman A et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl Cancer Inst. 1996;88:956-965.
47. Sarkaria JN. Tibbetts RS, Busby EC et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998;58:4375-4382.
48. Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999; 59:4375-4382.
49. Fairbairn DW, Olive PL, O'Neill KL. The comet assay: a comprehensive review. Mutat Res. 1995;339:37-59.
50. Francois S, El BJ, Dang PM et al. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol. 2005;174:3633-3642.
51. Power CP, Wang JH, Manning B et al. Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD 14 and TLR-2. J Immunol. 2004;173: 5229-5237.
52. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-lgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996;157: 4918-4925.
53. Yi AK, Yoon JG, Krieg AM. Convergence of CpG DNA-and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappa B activation pathways: regulation by mitogen-activated protein kinases. Int Immunol. 2003;15:577-591.
54. Chu W, Gong X, Li Z et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell. 2000;103:909-918.
55. Hacker H. Vabulas RM, Takeuchi O et al. Immune cell activation by bacterial GpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med. 2000;192:595-600.
56. Ojaniemi M, Glumoff V, Harju K et al. Phosphati-dylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol. 2003;33:597-605.
57. Janumyan YM, Sansam CG. Chattopadhyay A et al. Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 2003;22:5459-5470.
58. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006:13:1351-1359.
59. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol. 1995;13: 513-543.
60. Mirkovic N, Voehringer DW, Story MD et al. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene. 1997;15:1461-1470.
61. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA. 1996;93:9545-9552.
62. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15:2177-2196.
63. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998;282:1893-1897.
64. Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 2001;20:1839-1851.
65. Liu PK, Kraus E, Wu TA, Strong LC, Tainsky MA. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene. 1996;12:2267-2278.
66. Sanchez Y, Desany BA, Jones WJ et al. Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science. 1996;271:357-360.
67. Adamson AW, Beardsley Dl, Kim WJ et al. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell. 2005;16:1513-1526.
68. Brown KD, Rathi A, Kamath R et al. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet. 2003;33:80-84.
69. Wang Y, Cortez D, Yazdi P et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000;14:927-939.
70. Wang Y, Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci USA. 2003;100:15387-15392.
71. den EN, Kosoy A, Christopoulos H, O'Connell MJ. Resisting arrest: recovery from checkpoint arrest through dephosphorylation of Chk1 by PP1. Cell Cycle. 2004;3:529-533.
72. Ai L, Tao Q, Zhong S et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 2006;27:1341-1348.
73. Sturgeon CM, Knight ZA, Shokat KM, Roberge M. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006;5:885-892.
74. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol. 2004;16:130-136.
75. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655-666.